Aprotinin in cardiac surgery : more risks than usefulness?
Antifibrinolytic therapy with the serine protease inhibitor Aprotinin or the lysine analogues epsilon-aminocapronic acid or tranexamic acid is a therapeutic measure to reduce perioperative blood loss during cardiac surgery. In an international, prospective, non-randomised phase 4 observation study, Mangano et al. investigated the effectiveness and side-effects of Aprotinin, epsilon-aminocapronic acid and tranexamic acid in comparison to no antifibrinolytic therapy in a total of 4,374 patients who underwent cardiac surgery with extracorporeal circulation. In the opinion of Mangano et al. the results of this study question the safety and effectiveness of Aprotinin for reduction of perioperative blood loss by cardiac surgery patients. Despite a critical review of the study and results reported by Mangano et al., the authors of the present paper come to the conclusion that, in view of the availability of more reasonably priced alternatives in Germany, it appears to be sensible to give preference to tranexamic acid instead of aprotinin.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2006 |
|---|---|
| Erschienen: |
2006 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Der Anaesthesist - 55(2006), 9 vom: 09. Sept., Seite 989-92, 994-6 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Aprotinin in der Kardiochirurgie: Mehr Risiko als Nutzen? |
|---|
| Beteiligte Personen: |
Bremerich, D H [VerfasserIn] |
|---|
| Themen: |
6T84R30KC1 |
|---|
| Anmerkungen: |
Date Completed 26.01.2007 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM164450211 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM164450211 | ||
| 003 | DE-627 | ||
| 005 | 20231223102533.0 | ||
| 007 | tu | ||
| 008 | 231223s2006 xx ||||| 00| ||ger c | ||
| 028 | 5 | 2 | |a pubmed24n0548.xml |
| 035 | |a (DE-627)NLM164450211 | ||
| 035 | |a (NLM)16874472 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Bremerich, D H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Aprotinin in cardiac surgery |b more risks than usefulness? |
| 246 | 3 | 3 | |a Aprotinin in der Kardiochirurgie: Mehr Risiko als Nutzen? |
| 264 | 1 | |c 2006 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2007 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Antifibrinolytic therapy with the serine protease inhibitor Aprotinin or the lysine analogues epsilon-aminocapronic acid or tranexamic acid is a therapeutic measure to reduce perioperative blood loss during cardiac surgery. In an international, prospective, non-randomised phase 4 observation study, Mangano et al. investigated the effectiveness and side-effects of Aprotinin, epsilon-aminocapronic acid and tranexamic acid in comparison to no antifibrinolytic therapy in a total of 4,374 patients who underwent cardiac surgery with extracorporeal circulation. In the opinion of Mangano et al. the results of this study question the safety and effectiveness of Aprotinin for reduction of perioperative blood loss by cardiac surgery patients. Despite a critical review of the study and results reported by Mangano et al., the authors of the present paper come to the conclusion that, in view of the availability of more reasonably priced alternatives in Germany, it appears to be sensible to give preference to tranexamic acid instead of aprotinin | ||
| 650 | 4 | |a Clinical Trial, Phase IV | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Aminocaproates |2 NLM | |
| 650 | 7 | |a Antifibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Hemostatics |2 NLM | |
| 650 | 7 | |a Tranexamic Acid |2 NLM | |
| 650 | 7 | |a 6T84R30KC1 |2 NLM | |
| 650 | 7 | |a Aprotinin |2 NLM | |
| 650 | 7 | |a 9087-70-1 |2 NLM | |
| 700 | 1 | |a Strametz, R |e verfasserin |4 aut | |
| 700 | 1 | |a Kirchner, R |e verfasserin |4 aut | |
| 700 | 1 | |a Moritz, A |e verfasserin |4 aut | |
| 700 | 1 | |a Zwissler, B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Anaesthesist |d 1952 |g 55(2006), 9 vom: 09. Sept., Seite 989-92, 994-6 |w (DE-627)NLM00001253X |x 1432-055X |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2006 |g number:9 |g day:09 |g month:09 |g pages:989-92, 994-6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2006 |e 9 |b 09 |c 09 |h 989-92, 994-6 | ||